An interventional study of Cultural CBSM and Standard CBSM in Prostate Neoplasm, Genital Neoplasms, Male and Urogenital Neoplasms, sponsored by University of Miami. Completed at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by University of Miami · Not applicable, Interventional, and Supportive care
Among 21 studies in Prostatic Neoplasms by University of Miami — 7 open to participants now, 12 under way, none of them phase 3. Prostatic Neoplasms · University of Miami.
Among the 21 studies in Prostatic Neoplasms by University of Miami, this one is the 3rd largest by enrollment of the 18 interventional ones, is the only one that started in 2017, is one of 12 with no phase, and was the 12th registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
This study's enrollment of 188 is above the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →7 of the 21 studies in Prostatic Neoplasms by University of Miami are open now, in 1 country. Each count lists the studies.
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2017.
Median enrollment 44 across the 18 interventional studies, 144 across the 3 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
7 of the studies in Prostatic Neoplasms by University of Miami that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01794403University of MiamiRadiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer | 2027-02-01 |
| NCT06487507University of MiamiMetabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS) | 2027-05-01 |
| NCT04240327University of MiamiMarker Driven Selection of Patients for Prostate Biopsy and Management | 2027-06-01 |
| NCT02997709University of MiamiCollection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients | 2027-06-30 |
| NCT06392295University of MiamiPSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer | 2027-08-01 |
Among the 21 studies in Prostatic Neoplasms by University of Miami, from their registry updates:
The purpose of this study is to look at the effects of a 10-week stress management in-person group program. The program will study emotions, stress, and stress management techniques (such as relaxation and coping techniques) on quality of life, distress, depression, and physical health in Spanish- speaking, Hispanic/Latino men diagnosed with Prostate Cancer (PC).
This 5-year study evaluates the effects of a 10-week group-based linguistically translated and culturally adapted cognitive-behavioral stress and self-management (C-CBSM) intervention on symptom burden and health related quality of life (HRQoL) in Hispanic men treated for localized prostate cancer (PC). About 80% PC cases are diagnosed as early disease and have a 5- and 10-year survival rate of almost 100% and 99%, respectively.1 Most patients receive active treatment (\~70%) leading to prolonged treatment-related side effects and dysfunction persisting well beyond primary treatment. Survival is offset by chronic side effects such as sexual and urinary dysfunction, pain and fatigue that can lead to poor psychosocial functioning, impaired intimacy and social functioning, and masculinity concerns. Hispanic PC survivors report lower physical and social functioning, poorer emotional well-being and greater sexual and urinary dysfunction, even after accounting for SES and disease severity. These sequelae can lead to elevated glucocorticoid release and inflammatory cytokines that have a direct effect on these symptoms and can interfere with physiological pathways necessary for recovery of sexual and urinary functioning. We have shown that CBSM reduces symptom burden and improves HRQoL in bilingual Hispanic PC survivors. In a pilot we showed that a linguistic translation of CBSM with attention to sociocultural processes improved symptom burden and HRQoL in Spanish monolingual PC survivors. We have also shown that CBSM is associated with reduced glucocorticoid resistance and inflammatory gene expression pathways in circulating leukocytes among breast cancer survivors. We propose to (a) deliver a culturally adapted C-CBSM intervention in Spanish that places greater emphasis on salient sociocultural determinants of symptom burden and HRQoL in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo), (b) incorporate a neuroimmune model of symptom regulation and management, and (c) test the efficacy of C-CBSM, relative to standard non-culturally adapted CBSM, in two diverse Hispanic communities (Chicago \& Miami). We will test our aims in 200 Hispanic men post-treatment for localized PC with elevated symptom burden in a 2 x 4 randomized design with condition (C-CSBM vs. CBSM) as the between groups factors, and time (baseline, post-intervention \& 6- and 12-months post intervention) as the within groups factor.
Our Primary Aim is to determine whether randomization to C-CBSM, relative to standard CBSM, is associated with reduced symptom burden and improved HRQoL. Our Secondary Aims evaluate whether C-CBSM leads to greater improvements in the intervention targets (e.g., stress management, psychological distress \& interpersonal disruption), and physiologic adaptation (i.e., glucocorticoid receptor sensitivity \& inflammatory gene expression). We will also evaluate psychosocial and physiological mechanisms as mediators of C-CBSM's effects on our primary outcomes. We also explore several moderators (e.g., SES, acculturation, treatment, Hispanic origin) of CCBSM's effect on primary outcomes and the effects of C-CBSM on cardiometabolic health (e.g., lipids, fasting glucose) via reduced inflammation.
Primary Aim:
Aim 1: Determine whether participation in C-CBSM is associated with significantly greater reductions in symptom burden and improvements in HRQoL relative to participation in CBSM.
Secondary Aims:
Aim 2: Determine whether participation in C-CBSM is associated with significantly greater improvements in intervention targets (i.e., improved stress management, and reduced psychological distress and interpersonal disruption) relative to participation in the CBSM condition.
Exploratory Aims:
Aim 3: Explore whether participation in C-CBSM is associated with significantly greater activation of leukocyte glucocorticoid receptor and less inflammatory gene expression profiles relative to CBSM.
Aim 4: Explore whether C-CBSM related improvements in symptom burden and HRQoL are mediated by improvements in intervention targets and gene expression profiles.
Aim 5: Explore moderators of C-CBSM (e.g., SES, treatment type, acculturation, Hispanic ancestry) and CCBSM's effects on cardiometabolic markers via reduced inflammation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals scoring >3 on the SPMSQ will be excluded or per PI discretion based on a case by case review.
.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
Behavioral: Cultural CBSM
Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
Behavioral: Standard CBSM
The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
Change in Symptom Burden as Measure by EPIC-S.
Symptom Burden will be measured using the 5-item sexual domain of the Expanded Prostate Cancer Index Composite (EPIC) - Short Form (EPIC-S). All items are transformed to a 0-100 scale and averaged to calculate the domain summary scores, where higher scores indicate better functioning and less bother.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in HRQoL as Measured by the FACT Questionnaire.
HRQoL will be measured using Functional Assessment of Cancer Therapy - Prostate (FACT-P) including 4 domains of the FACT-General (FACT-G). The questionnaire has 39 items, with the total score ranging from 0-156. Higher scores indicate better function.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Symptom Burden as Measure by EPIC-UIN.
Symptom Burden will be measured using the 9-item urinary domain of the Expanded Prostate Cancer Index Composite (EPIC) - Short Form (EPIC-UIN). All items are transformed to a 0-100 scale and averaged to calculate the domain summary scores, where higher scores indicate better functioning and less bother.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in HRQoL as Measured by the PROMIS Fatigue Questionnaire
HRQoL will be measured using Patient-Reported Outcome Measurement Information System (PROMIS) short form for Fatigue Questionnaire. The PROMIS Fatigue measure generates t-scores with a mean of 50 and a standard deviation of 10. Scores typically range from approximately 30 to 80. Higher scores indicate greater fatigue.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in HRQoL as Measured by the PROMIS Pain Questionnaire
HRQoL will be measured using the PROMIS short form for Pain Interference Questionnaire. The items are item banks, and scoring is done via a computer adaptive test (CAT), which utilizes item response theory (IRT) to calculate a score that is then transformed into a T-score with a mean of 50 and a standard deviation of 10. Scores typically range from approximately 30 to 80. Items are administered in an iterative approach where subsequent items are calibrated on prior ones. Once standard error reaches 2 or less, the CAT stops administering items. Higher scores indicate greater pain interference.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Stress Management Skills as Measured by MOCS-A
Stress management skills will be measured using the Measure of Current Status Part A (MOCS-A) Questionnaire. MOCS-A is a 13-item questionnaire with a total score ranging from 0 - 52 with the higher score indicating greater stress management skills.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Prostate Cancer-specific Psychological Distress as Measured by MAX-PC - Section I-II
Psychological distress will be measured using the Memorial Anxiety Scale for Prostate Cancer Patients (MAX-PC) Questionnaire. The MAX-PC sections I-II is a 14-item questionnaire with a total score ranging from 0-42 with the higher score indicating increased distress.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Prostate Cancer-specific Psychological Distress as Measured by MAX-PC - Section III
Psychological distress will be measured using the Memorial Anxiety Scale for Prostate Cancer Patients (MAX-PC) Questionnaire. The MAX-PC section III is a 4-item questionnaire with a total score ranging from 0-12 with the lower score indicating increased distress.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Psychosocial Distress as Measured by the PROMIS Depression Questionnaire
PROMIS-Depression is a 28-item questionnaire with a total score ranging from 28-140 with the higher score indicating increased symptoms of depression.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Psychosocial Distress as Measured by the PROMIS Anxiety Questionnaire
PROMIS-Anxiety is a 29-item questionnaire with a total score ranging from 29-145 with the higher score indicating increased symptoms of anxiety.
Time frame: Baseline, Month 3, Month 6, Month 12
Change in Interpersonal Function as Measured the SIP Questionnaire
Sickness Impact Profile (SIP) is a 20-item questionnaire responded with a yes or no. The total number of yes responses will be scored as 1 point with the total score ranging from 0-20 with the higher score indicating poor interpersonal function.
Time frame: Baseline, Month 3, Month 6, Month 12
| Milestone | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Started | 100 | 88 |
| Completed | 82 | 70 |
| Not completed | 18 | 18 |
| Withdrew: Withdrawal by subject | 18 | 16 |
| Withdrew: Lost to follow-up | 0 | 2 |
Symptom Burden will be measured using the 5-item sexual domain of the Expanded Prostate Cancer Index Composite (EPIC) - Short Form (EPIC-S). All items are transformed to a 0-100 scale and averaged to calculate the domain summary scores, where higher scores indicate better functioning and less bother.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 30.1 ± 2.53 | 32.1 ± 3.02 |
| Month 3 | 34.7 ± 3.01 | 35.8 ± 3.30 |
| Month 6 | 35.9 ± 3.39 | 38.0 ± 3.67 |
| Month 12 | 36.2 ± 3.27 | 38.9 ± 3.50 |
HRQoL will be measured using Functional Assessment of Cancer Therapy - Prostate (FACT-P) including 4 domains of the FACT-General (FACT-G). The questionnaire has 39 items, with the total score ranging from 0-156. Higher scores indicate better function.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 81.1 ± 1.12 | 81.7 ± 1.70 |
| Month 3 | 83.8 ± 1.30 | 83.7 ± 1.45 |
| Month 6 | 83.6 ± 1.51 | 83.3 ± 1.74 |
| Month 12 | 82.6 ± 1.41 | 83.0 ± 1.54 |
Symptom Burden will be measured using the 9-item urinary domain of the Expanded Prostate Cancer Index Composite (EPIC) - Short Form (EPIC-UIN). All items are transformed to a 0-100 scale and averaged to calculate the domain summary scores, where higher scores indicate better functioning and less bother.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 73.5 ± 2.45 | 78.8 ± 2.32 |
| Month 3 | 77.4 ± 2.50 | 82.2 ± 2.38 |
| Month 6 | 79.5 ± 2.47 | 84.6 ± 2.18 |
| Month 12 | 78.3 ± 2.41 | 83.3 ± 2.31 |
HRQoL will be measured using Patient-Reported Outcome Measurement Information System (PROMIS) short form for Fatigue Questionnaire. The PROMIS Fatigue measure generates t-scores with a mean of 50 and a standard deviation of 10. Scores typically range from approximately 30 to 80. Higher scores indicate greater fatigue.
| T-score | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 43.2 ± 0.90 | 43.5 ± 0.99 |
| Month 3 | 43.3 ± 0.88 | 42.8 ± 1.06 |
| Month 6 | 43.9 ± 1.09 | 43.1 ± 1.05 |
| Month 12 | 43.5 ± 0.96 | 43.0 ± 0.99 |
HRQoL will be measured using the PROMIS short form for Pain Interference Questionnaire. The items are item banks, and scoring is done via a computer adaptive test (CAT), which utilizes item response theory (IRT) to calculate a score that is then transformed into a T-score with a mean of 50 and a standard deviation of 10. Scores typically range from approximately 30 to 80. Items are administered in an iterative approach where subsequent items are calibrated on prior ones. Once standard error reaches 2 or less, the CAT stops administering items. Higher scores indicate greater pain interference.
| T-score | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 47.8 ± 0.93 | 47.0 ± 0.97 |
| Month 3 | 46.7 ± 0.96 | 46.4 ± 1.08 |
| Month 6 | 47.1 ± 1.20 | 46.9 ± 1.06 |
| Month 12 | 48.3 ± 1.07 | 46.2 ± 1.02 |
Stress management skills will be measured using the Measure of Current Status Part A (MOCS-A) Questionnaire. MOCS-A is a 13-item questionnaire with a total score ranging from 0 - 52 with the higher score indicating greater stress management skills.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 38.5 ± 0.87 | 37.6 ± 1.09 |
| Month 3 | 38.6 ± 0.91 | 38.3 ± 1.09 |
| Month 6 | 39.6 ± 0.93 | 39.3 ± 1.23 |
| Month 12 | 39.2 ± 0.90 | 38.0 ± 0.95 |
Psychological distress will be measured using the Memorial Anxiety Scale for Prostate Cancer Patients (MAX-PC) Questionnaire. The MAX-PC sections I-II is a 14-item questionnaire with a total score ranging from 0-42 with the higher score indicating increased distress.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 7.1 ± 0.94 | 10.0 ± 1.20 |
| Month 3 | 5.6 ± 0.98 | 6.2 ± 0.97 |
| Month 6 | 5.01 ± 0.93 | 7.7 ± 1.24 |
| Month 12 | 6.7 ± 1.08 | 6.1 ± 0.94 |
Psychological distress will be measured using the Memorial Anxiety Scale for Prostate Cancer Patients (MAX-PC) Questionnaire. The MAX-PC section III is a 4-item questionnaire with a total score ranging from 0-12 with the lower score indicating increased distress.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 8.5 ± 0.28 | 8.1 ± 0.37 |
| Month 3 | 8.9 ± 0.31 | 9.1 ± 0.33 |
| Month 6 | 8.7 ± 0.29 | 8.3 ± 0.38 |
| Month 12 | 9.1 ± 0.30 | 8.8 ± 0.35 |
PROMIS-Depression is a 28-item questionnaire with a total score ranging from 28-140 with the higher score indicating increased symptoms of depression.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 44.8 ± 0.91 | 45.9 ± 0.96 |
| Month 3 | 43.8 ± 0.94 | 44.7 ± 1.05 |
| Month 6 | 44.8 ± 1.05 | 45.4 ± 1.12 |
| Month 12 | 45.5 ± 0.97 | 44.9 ± 1.10 |
PROMIS-Anxiety is a 29-item questionnaire with a total score ranging from 29-145 with the higher score indicating increased symptoms of anxiety.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 49.5 ± 0.98 | 50.0 ± 1.08 |
| Month 3 | 50.4 ± 0.96 | 49.1 ± 1.18 |
| Month 6 | 51.0 ± 1.16 | 49.8 ± 1.24 |
| Month 12 | 50.7 ± 0.98 | 49.0 ± 1.15 |
Sickness Impact Profile (SIP) is a 20-item questionnaire responded with a yes or no. The total number of yes responses will be scored as 1 point with the total score ranging from 0-20 with the higher score indicating poor interpersonal function.
| score on a scale | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| Baseline | 2.5 ± 0.28 | 3.1 ± 0.38 |
| Month 3 | 2.6 ± 0.40 | 2.9 ± 0.45 |
| Month 6 | 2.2 ± 0.30 | 2.5 ± 0.40 |
| Month 12 | 2.6 ± 0.38 | 2.3 ± 0.36 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cultural-Cognitive Behavioral Stress Management (CCBSM) | 0/100 (0%) | 0/100 (0%) | 3/100 (3%) |
| Cognitive Behavioral Stress Management (CBSM) | 0/88 (0%) | 3/88 (3.4%) | 7/88 (8%) |
| Event | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| InjuryInjury, poisoning and procedural complications | 0/100 | 1/88 |
| InsomniaPsychiatric disorders | 0/100 | 1/88 |
| HypertensionCardiac disorders | 0/100 | 1/88 |
| Event | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) |
|---|---|---|
| AnxietyPsychiatric disorders | 1/100 | 2/88 |
| DepressionPsychiatric disorders | 0/100 | 2/88 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 0/100 | 1/88 |
| FallInjury, poisoning and procedural complications | 1/100 | 1/88 |
| InjuryInjury, poisoning and procedural complications | 0/100 | 1/88 |
| COVID-19Infections and infestations | 1/100 | 0/88 |
| Age, Continuous(years) | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) | Total |
|---|---|---|---|
| Mean | 66.07 ± 7.64 | 65.42 ± 8.42 | 65.77 ± 8.0 |
| Sex: Female, Male(Participants) | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 100 | 88 | 188 |
| Ethnicity (NIH/OMB)(Participants) | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) | Total |
|---|---|---|---|
| Hispanic or Latino | 100 | 88 | 188 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cultural-Cognitive Behavioral Stress Management (CCBSM) | Cognitive Behavioral Stress Management (CBSM) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 75 | 72 | 147 |
| More than one race | 15 | 10 | 25 |
| Unknown or Not Reported | 6 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.